GLYCANOSTICS SRO

Their core work

Glycanostics is a Bratislava-based biotech SME that develops glycan-based diagnostic tools for cancer detection. Glycans — the sugar structures attached to proteins — carry disease signatures that conventional protein biomarkers miss, and Glycanostics specialises in turning this science into practical clinical assays. Their work spans both the research-validation phase (participating in an ERC Proof of Concept project on prostate cancer detection protocols) and the commercialisation phase (coordinating their own SME Instrument project on glycan-based cancer diagnostics). In practice, they translate glycan chemistry from laboratory research into reliable, reproducible assay formats suitable for clinical or industrial use.

What they specialise in

How they've shifted over time

With only two projects concentrated in 2018–2019, a full evolution curve is not possible, but the directional shift is meaningful. They began as a participant in an ERC Proof of Concept grant (Andrea), the funding instrument that bridges academic discovery and market application — suggesting the company either spun out of, or closely collaborated with, an ERC-funded research group. Within roughly a year they moved to independently coordinating an SME Instrument Phase 1 project (GlyCan), the EU's dedicated pathway for early-stage commercial validation. This arc — from research participant to commercial coordinator — is the classic spin-off trajectory, and it happened very fast.

Glycanostics appears to be moving from academic co-development toward independent product ownership, with the glycan-cancer diagnostics angle as their core commercial bet — making them a candidate partner for anyone seeking a science-grounded SME with a proprietary diagnostic concept.

How they like to work

Glycanostics has worked in extremely small teams — just one unique consortium partner across both projects, all within a single country. They have played both the participant role (in the ERC-POC) and the coordinator role (in the SME-1), showing they can operate on either side of the leadership table. Anyone engaging them should expect a tight, bilateral working relationship rather than a broad multi-partner consortium dynamic; they are a focused specialist, not a network hub.

Glycanostics has collaborated with just one partner across its two H2020 projects, entirely within a single country (Slovakia). Their network is narrow by design or by stage — consistent with a very young spin-off that has not yet built a wider European partner base.

What sets them apart

Glycanostics occupies a genuinely specific niche: applying glycan chemistry — the analysis of sugar-protein modifications — to cancer early detection, a field where most diagnostics companies still focus on conventional protein or genetic biomarkers. The company name itself encodes their differentiation (glycan + diagnostics). Their dual credibility — ERC-grade scientific validation on one side and an SME Instrument commercial track record on the other — makes them a credible bridge between frontier research and diagnostic product development, which is rare at this company size.

Highlights from their portfolio

• GlyCan
  Glycanostics coordinated this SME Instrument Phase 1 project, demonstrating independent ownership of a commercial glycan-based cancer diagnostics concept and the ability to lead an EU-funded initiative.
• Andrea
  Participation in an ERC Proof of Concept project — a highly competitive instrument reserved for frontier research spin-outs — signals direct lineage from academically validated science in prostate cancer detection.